GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

GSK plcNYSE: GSK

EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026

EPS (Basic) dips below year-ago levels

Q2 FY2026 EPS (Basic) of £0.22 fell 69.4% year over year, behind the +41.9% change in trailing-twelve-month EPS (Basic). Sequentially, it fell 74.4% from the prior quarter. Over 3 fiscal years it compounded at -27.6% a year.

Context

  • EPS (Basic) increased in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 7 analysts of £3.63 (+28.6%) for the fiscal year ending Dec 2026, a slowdown from the +123.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
£0.22-74.4% QoQ
Last fiscal yearDec 2025
£2.82+123.8% YoY
LTMJun 2026
£2.4+41.9% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.4%+1.0%+70.4 pp
1 year+123.8%+28.6%-95.2 pp
3-year CAGR-27.6%+12.0%+39.6 pp
5-year CAGR+9.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

GBP · from the income statement

Latest · FY2025
2.82 GBP
Year-over-year change
+123.8%
4-year CAGR
+0.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +41.9% is the 2nd highest of 10, against a peer median of -3.5%.
  • Over three fiscal years its annual growth of -27.6% compares with a peer median of +17.3%.
GSK Competitors
EPS (Basic) for GSK and competitors
Company Period LTM YoY 3-year CAGR
LLYEli Lilly and CompanyLTM Jun 2026$29.89 USD+94.6%+52.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 26.23 DKK+5.0%+23.4%
AMGNAmgen Inc.LTM Jun 2026$16.22 USD+31.7%+5.6%
AZNAstraZeneca PLCLTM Sep 2026$7.08 USD+17.0%+46.0%
NVSNovartis AGLTM Jun 2026$6.66 USD-3.5%+31.5%
JNJJohnson & JohnsonLTM Sep 2026$6.6 USD-36.8%+17.3%
GSKGSK plcLTM Jun 2026£2.4 GBP+41.9%-27.6%
MRKMerck & Co., Inc.LTM Jun 2026$1.26 USD-80.6%+8.4%
PFEPfizer Inc.LTM Jun 2026$0.76 USD-60.1%-37.6%
SNYSanofiLTM Jun 2026€0.48 EUR-87.5%+0.1%
Peer median (excluding GSK) —-3.5%+17.3%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.